Amphetamine Cocaine Interaction Study - 2

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00000305

Recruitment Status : Terminated (Original P.I. left the institution)

First Posted : September 21, 1999

Last Update Posted : May 18, 2012

Sponsor:

Collaborators:

National Institute on Drug Abuse (NIDA)

University of Texas

Information provided by (Responsible Party):

The University of Texas Health Science Center, Houston

Tracking Information

First Submitted Date ^ICMJE

September 20, 1999

First Posted Date ^ICMJE

September 21, 1999

Last Update Posted Date

May 18, 2012

Study Start Date ^ICMJE

Not Provided

Primary Completion Date

Not Provided

Current Primary Outcome Measures ^ICMJE

Not Provided

Original Primary Outcome Measures ^ICMJE

Mood indicators
Psychiatric interview
Craving
Drug use
Medication compliance
Retention
Addiction severity

Change History

Complete list of historical versions of study NCT00000305 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures ^ICMJE

Not Provided

Original Secondary Outcome Measures ^ICMJE

Not Provided

Current Other Pre-specified Outcome Measures

Not Provided

Original Other Pre-specified Outcome Measures

Not Provided

Descriptive Information

Brief Title ^ICMJE

Amphetamine Cocaine Interaction Study - 2

Official Title ^ICMJE

Amphetamine Cocaine Interaction Study

Brief Summary

The purpose of this study is to evaluate results of d-amphetamine - cocaine (pharmacology) interaction study.

Detailed Description

Not Provided

Study Type ^ICMJE

Interventional

Study Phase ^ICMJE

Phase 1

Study Design ^ICMJE

Primary Purpose: Treatment

Condition ^ICMJE

Cocaine-Related Disorders

Intervention ^ICMJE

Drug: Dextroamphetamine

Study Arms ^ICMJE

Not Provided

Publications *

Not Provided

* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.

Recruitment Information

Recruitment Status ^ICMJE

Terminated

Enrollment ^ICMJE

Original Enrollment ^ICMJE

Same as current

Study Completion Date ^ICMJE

Not Provided

Primary Completion Date

Not Provided

Eligibility Criteria ^ICMJE

Please contact site for information.

Sex/Gender ^ICMJE

Sexes Eligible for Study:

Male

Ages ^ICMJE

18 Years to 45 Years (Adult)

Accepts Healthy Volunteers ^ICMJE

Contacts ^ICMJE

Contact information is only displayed when the study is recruiting subjects

Listed Location Countries ^ICMJE

United States

Removed Location Countries

Administrative Information

NCT Number ^ICMJE

NCT00000305

Other Study ID Numbers ^ICMJE

NIDA-09262-2
P50DA009262 ( U.S. NIH Grant/Contract )
P50-09262-2

Has Data Monitoring Committee

Yes

U.S. FDA-regulated Product

Not Provided

IPD Sharing Statement ^ICMJE

Not Provided

Responsible Party

The University of Texas Health Science Center, Houston

Study Sponsor ^ICMJE

The University of Texas Health Science Center, Houston

Collaborators ^ICMJE

National Institute on Drug Abuse (NIDA)
University of Texas

Investigators ^ICMJE

Principal Investigator:

John Grabowski, Ph.D.

University of Texas

PRS Account

The University of Texas Health Science Center, Houston

Verification Date

May 2012

^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP

To Top